Previous research has shown that aberrant sphingolipid metabolism, which is evidenced by elevated levels of circulating ceramide, is associated with poor prognosis in patients with prostate cancer (PC). Work at the University of Adelaide has led to the establishment of a new syngeneic mouse model to study the role of sphingolipid metabolism in PC.
Researchers from Hebei Normal University and affiliated organizations presented the discovery and preclinical characterization of a novel B lymphoma Mo-MLV insertion region 1 (Bmi-1) expression inhibitor, APD-94, designed as an agent that could potentially overcome drug resistance in patients with colorectal cancer.
Ligachem Biosciences Inc. landed another exclusive licensing deal to develop and commercialize antibody-drug conjugates (ADCs), this time with T-cell receptor therapy specialist Daan Biotherapeutics Inc. for a cancer-targeting antibody.
Ligachem Biosciences Inc. landed another exclusive licensing deal to develop and commercialize antibody-drug conjugates (ADCs), this time with T-cell receptor therapy specialist Daan Biotherapeutics Inc. for a cancer-targeting antibody.
The market took a strong liking to the latest U.S. FDA guidance for Moleculin Biotech Inc.’s upcoming Miracle phase III trial testing annamycin in cancer. So much so that the company’s stock (NASDAQ:MBRX) soared 202% on Feb. 13 to close at $1.27 a share.
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 (F18-Pivalate) successfully detected brain metastases in a variety of primary solid tumors in a phase II study.
Work at Exelixis Inc. has led to the development of antibody-drug conjugates (ADCs) comprising antibodies targeting interleukin-13 receptor subunit α2 (IL-13RA2, IL-13R-α2) covalently linked to a payload. They are described as potentially useful for the treatment of non-small-cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC).
Researchers from Wuyi University presented the discovery and preclinical characterization of kinesin spindle protein (KSP) degraders developed using proteolysis-targeting chimera (PROTAC) technology.
Xilio Therapeutics Inc. has announced three wholly owned preclinical programs for masked T-cell engagers targeting prostate-specific membrane antigen (PSMA), claudin 18.2 (CLDN18.2) and six-transmembrane epithelial antigen of prostate 1 (STEAP1).
RSS
